Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation

Y. Li; T. Yokota; V. Gama; T. Yoshida; J. A. Gomez; K. Ishikawa; H. Sasaguri; H. Y. Cohen; D. A. Sinclair; H. Mizusawa; S. Matsuyama

doi:10.1038/sj.cdd.4402219

Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation

Y. Li, T. Yokota, V. Gama, T. Yoshida, J. A. Gomez, K. Ishikawa, H. Sasaguri, H. Y. Cohen, D. A. Sinclair, H. Mizusawa, S. Matsuyama

The Mina and Everard Goodman Faculty of Life Sciences

Research output: Contribution to journal › Article › peer-review

87 Scopus citations

Abstract

Polyglutamine (polyQ) diseases, such as Huntington's disease and Machado-Joseph disease (MJD), are caused by gain of toxic function of abnormally expanded polyQ tracts. Here, we show that expanded polyQ of ataxin-3 (Q79C), a gene that causes MJD, stimulates Ku70 acetylation, which in turn dissociates the proapoptotic protein Bax from Ku70, thereby promoting Bax activation and subsequent cell death. The Q79C-induced cell death was significantly blocked by Ku70 or Bax-inhibiting peptides (BIPs) designed from Ku70. Furthermore, expression of SIRT1 deacetylase and the addition of a SIRT1 agonist, resveratrol, reduced Q79C toxicity. In contrast, mimicking acetylation of Ku70 abolished the ability of Ku70 to suppress Q79C toxicity. These results indicate that Bax and Ku70 acetylation play important roles in Q79C-induced cell death, and that BIP may be useful in the development of therapeutics for polyQ diseases.

Original language	English
Pages (from-to)	2058-2067
Number of pages	10
Journal	Cell Death and Differentiation
Volume	14
Issue number	12
DOIs	https://doi.org/10.1038/sj.cdd.4402219
State	Published - Dec 2007

Bibliographical note

Funding Information:
Acknowledgements. We thank Dr. Akira Kakizuka for providing ataxin-3-expressing plasmid, Dr. Hideki Nishitoh for recombinant adenoviruses encoding Q79C and Q35C, Dr. Shinichirou Imai for providing mouse SIRT1 cDNA and Dr. Hideki Mochizuki for providing mouse tissue sample treated with MPTP as positive control of activated Bax. We also thank Ms. Keiko Kaneko, Ms. Kanae Yonetsu and Ms. Iku Sudo for their technical help. This work was supported in part by a grant from the 21st Century COE Program on Brain Integration and its Disorders to Tokyo Medical and Dental University (to YL and HM), Japan Foundation for Neuroscience and Mental Health (to YL, TY and HM), National Institute of Health (USA) (P20CA10373 to SM) and American Heart Association (to VG (predoctoral fellowship), JG (predoctoral fellowship) and SM (Grant-in-Aid)).

Funding

Acknowledgements. We thank Dr. Akira Kakizuka for providing ataxin-3-expressing plasmid, Dr. Hideki Nishitoh for recombinant adenoviruses encoding Q79C and Q35C, Dr. Shinichirou Imai for providing mouse SIRT1 cDNA and Dr. Hideki Mochizuki for providing mouse tissue sample treated with MPTP as positive control of activated Bax. We also thank Ms. Keiko Kaneko, Ms. Kanae Yonetsu and Ms. Iku Sudo for their technical help. This work was supported in part by a grant from the 21st Century COE Program on Brain Integration and its Disorders to Tokyo Medical and Dental University (to YL and HM), Japan Foundation for Neuroscience and Mental Health (to YL, TY and HM), National Institute of Health (USA) (P20CA10373 to SM) and American Heart Association (to VG (predoctoral fellowship), JG (predoctoral fellowship) and SM (Grant-in-Aid)).

Funders	Funder number
Japan Foundation for Neuroscience and Mental Health
National Institutes of Health	P20CA10373
American Heart Association

Access to Document

10.1038/sj.cdd.4402219

Cite this

@article{5690669c164549edbd90d14e83b92d6b,

title = "Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation",

abstract = "Polyglutamine (polyQ) diseases, such as Huntington's disease and Machado-Joseph disease (MJD), are caused by gain of toxic function of abnormally expanded polyQ tracts. Here, we show that expanded polyQ of ataxin-3 (Q79C), a gene that causes MJD, stimulates Ku70 acetylation, which in turn dissociates the proapoptotic protein Bax from Ku70, thereby promoting Bax activation and subsequent cell death. The Q79C-induced cell death was significantly blocked by Ku70 or Bax-inhibiting peptides (BIPs) designed from Ku70. Furthermore, expression of SIRT1 deacetylase and the addition of a SIRT1 agonist, resveratrol, reduced Q79C toxicity. In contrast, mimicking acetylation of Ku70 abolished the ability of Ku70 to suppress Q79C toxicity. These results indicate that Bax and Ku70 acetylation play important roles in Q79C-induced cell death, and that BIP may be useful in the development of therapeutics for polyQ diseases.",

author = "Y. Li and T. Yokota and V. Gama and T. Yoshida and Gomez, {J. A.} and K. Ishikawa and H. Sasaguri and Cohen, {H. Y.} and Sinclair, {D. A.} and H. Mizusawa and S. Matsuyama",

note = "Funding Information: Acknowledgements. We thank Dr. Akira Kakizuka for providing ataxin-3-expressing plasmid, Dr. Hideki Nishitoh for recombinant adenoviruses encoding Q79C and Q35C, Dr. Shinichirou Imai for providing mouse SIRT1 cDNA and Dr. Hideki Mochizuki for providing mouse tissue sample treated with MPTP as positive control of activated Bax. We also thank Ms. Keiko Kaneko, Ms. Kanae Yonetsu and Ms. Iku Sudo for their technical help. This work was supported in part by a grant from the 21st Century COE Program on Brain Integration and its Disorders to Tokyo Medical and Dental University (to YL and HM), Japan Foundation for Neuroscience and Mental Health (to YL, TY and HM), National Institute of Health (USA) (P20CA10373 to SM) and American Heart Association (to VG (predoctoral fellowship), JG (predoctoral fellowship) and SM (Grant-in-Aid)).",

year = "2007",

month = dec,

doi = "10.1038/sj.cdd.4402219",

language = "אנגלית",

volume = "14",

pages = "2058--2067",

journal = "Cell Death and Differentiation",

issn = "1350-9047",

publisher = "Springer Nature",

number = "12",

}

TY - JOUR

T1 - Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation

AU - Li, Y.

AU - Yokota, T.

AU - Gama, V.

AU - Yoshida, T.

AU - Gomez, J. A.

AU - Ishikawa, K.

AU - Sasaguri, H.

AU - Cohen, H. Y.

AU - Sinclair, D. A.

AU - Mizusawa, H.

AU - Matsuyama, S.

N1 - Funding Information: Acknowledgements. We thank Dr. Akira Kakizuka for providing ataxin-3-expressing plasmid, Dr. Hideki Nishitoh for recombinant adenoviruses encoding Q79C and Q35C, Dr. Shinichirou Imai for providing mouse SIRT1 cDNA and Dr. Hideki Mochizuki for providing mouse tissue sample treated with MPTP as positive control of activated Bax. We also thank Ms. Keiko Kaneko, Ms. Kanae Yonetsu and Ms. Iku Sudo for their technical help. This work was supported in part by a grant from the 21st Century COE Program on Brain Integration and its Disorders to Tokyo Medical and Dental University (to YL and HM), Japan Foundation for Neuroscience and Mental Health (to YL, TY and HM), National Institute of Health (USA) (P20CA10373 to SM) and American Heart Association (to VG (predoctoral fellowship), JG (predoctoral fellowship) and SM (Grant-in-Aid)).

PY - 2007/12

Y1 - 2007/12

N2 - Polyglutamine (polyQ) diseases, such as Huntington's disease and Machado-Joseph disease (MJD), are caused by gain of toxic function of abnormally expanded polyQ tracts. Here, we show that expanded polyQ of ataxin-3 (Q79C), a gene that causes MJD, stimulates Ku70 acetylation, which in turn dissociates the proapoptotic protein Bax from Ku70, thereby promoting Bax activation and subsequent cell death. The Q79C-induced cell death was significantly blocked by Ku70 or Bax-inhibiting peptides (BIPs) designed from Ku70. Furthermore, expression of SIRT1 deacetylase and the addition of a SIRT1 agonist, resveratrol, reduced Q79C toxicity. In contrast, mimicking acetylation of Ku70 abolished the ability of Ku70 to suppress Q79C toxicity. These results indicate that Bax and Ku70 acetylation play important roles in Q79C-induced cell death, and that BIP may be useful in the development of therapeutics for polyQ diseases.

AB - Polyglutamine (polyQ) diseases, such as Huntington's disease and Machado-Joseph disease (MJD), are caused by gain of toxic function of abnormally expanded polyQ tracts. Here, we show that expanded polyQ of ataxin-3 (Q79C), a gene that causes MJD, stimulates Ku70 acetylation, which in turn dissociates the proapoptotic protein Bax from Ku70, thereby promoting Bax activation and subsequent cell death. The Q79C-induced cell death was significantly blocked by Ku70 or Bax-inhibiting peptides (BIPs) designed from Ku70. Furthermore, expression of SIRT1 deacetylase and the addition of a SIRT1 agonist, resveratrol, reduced Q79C toxicity. In contrast, mimicking acetylation of Ku70 abolished the ability of Ku70 to suppress Q79C toxicity. These results indicate that Bax and Ku70 acetylation play important roles in Q79C-induced cell death, and that BIP may be useful in the development of therapeutics for polyQ diseases.

UR - http://www.scopus.com/inward/record.url?scp=36249024811&partnerID=8YFLogxK

U2 - 10.1038/sj.cdd.4402219

DO - 10.1038/sj.cdd.4402219

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 17885668

AN - SCOPUS:36249024811

SN - 1350-9047

VL - 14

SP - 2058

EP - 2067

JO - Cell Death and Differentiation

JF - Cell Death and Differentiation

IS - 12

ER -

Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation

Abstract

Bibliographical note

Funding

Access to Document

Other files and links

Fingerprint

Cite this